Project Grant R35CA305347
Award Date 8/20/25
Completion Date 7/31/32
Dollars Obligated $1.1M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, USA
Similar Awards
- The National Cancer Institute awarded a $2,489,032 Project Grant to the Sloan-Kettering Institute for Cancer Research on August 1, 2025 under the Cancer Biology Research program (CFDA 93.396). The grant will fund a 5-year research program to investigate the role of lipid metabolism in ferroptosis, a novel cell death process, and explore innovative therapeutic approaches for treating aggressive, drug-resistant cancers. The program consists of three highly integrated projects led by researchers at...
- This federal Project Grant award of $2,808,108.00, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research conducted by the Sloan-Kettering Institute for Cancer Research to investigate the role of clonal hematopoiesis in therapeutic resistance and metastatic relapse in breast cancer. The award period extends from March 1, 2024 to February 29, 2028. Through this funding, the Sloan-Kettering Institute will explore the...
- This federal Project Grant award of $205,700 from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) supports research at the Sloan-Kettering Institute for Cancer Research in New York aimed at understanding and overcoming rapid resistance to targeted therapies in colorectal cancer. The key objectives are to evaluate how intrinsic tumor features modulate the development of resistance to targeted therapies, and to test a novel combination approach to...
- The National Cancer Institute (NCI) awarded a $1,034,176 Project Grant to the Sloan-Kettering Institute for Cancer Research under the Cancer Biology Research program (CFDA 93.396) with an award date of August 18, 2025. The grant aims to understand the mechanisms of aberrant RNA splicing and how it drives the development of various hematological malignancies, including myelodysplastic syndrome, chronic lymphocytic leukemia, and acute myeloid leukemia. The research builds on the institution's past...
- This $292,028 Project Grant awarded by the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) supports research to investigate the mechanisms by which oncogene amplification leads to genome instability and the development of therapy-resistant cancer clones. The research will be conducted by the Sloan-Kettering Institute for Cancer Research in New York and is scheduled to run from August 1, 2025 to July 31, 2030. Using single-cell genomic sequencing techniques, the project aims...
- The Sloan-Kettering Institute for Cancer Research was awarded a $581,381 Project Grant by the National Cancer Institute (CFDA 93.393 Cancer Cause and Prevention Research) to investigate the role of microhomology-mediated end-joining (MMEJ) in mitosis and its impact on drug resistance. The project aims to gain a better understanding of DNA damage repair pathways and how they go awry in cancer, with the goal of informing more effective therapeutic approaches. Specifically, the research will...
- The National Cancer Institute (NCI) awarded a $3,111,184 Project Grant under the Cancer Biology Research program (CFDA 93.396) to the Sloan-Kettering Institute for Cancer Research. The grant supports research to investigate the oncogenic mechanisms of the NPM1::TYK2 gene fusion and its role in driving the development of mature T-cell lymphomas, specifically anaplastic large cell lymphoma (ALCL). The project aims to advance the understanding of how this genetic alteration promotes lymphomagenesis...
- The National Cancer Institute (CFDA 93.398 Cancer Research Manpower) awarded a $147,486 Project Grant to the Sloan-Kettering Institute for Cancer Research to support a 3-year research training program in cellular immunology and mechanobiology. The program aims to examine how the mechanical properties of the tumor microenvironment influence metastatic site preference and immune system response. Key research activities include in vivo modeling, biophysical measurements, and single-cell analysis to...
- This $238,722 federal Project Grant awarded on August 18, 2025 by the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) to the Sloan-Kettering Institute for Cancer Research supports research to investigate the role of mutagenic DNA repair during the persistence of cancer cells. The research aims to define the specific mechanisms that promote mutagenic DNA repair and drive acquired drug resistance in persister cancer cells, focusing on the role of the microhomology-mediated end...
- The National Cancer Institute (CFDA 93.396 - Cancer Biology Research) awarded a $1,625,853 Project Grant to New York University (NYU) on December 13, 2024. The grant will support NYU's research to map and characterize the role of 3D "hubs" - regulatory DNA elements that interact with multiple loci - in the context of T-cell leukemia (T-ALL), early T-cell progenitor leukemia (ETP-ALL), and T-cell lymphoma. The project aims to better define how these 3D chromatin structures are rewired...